Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice
Language English Country New Zealand Media print
Document type Journal Article
PubMed
27541802
DOI
10.1007/s40266-016-0390-1
PII: 10.1007/s40266-016-0390-1
Knihovny.cz E-resources
- MeSH
- Time-to-Treatment MeSH
- Indoles administration & dosage adverse effects therapeutic use MeSH
- Carcinoma, Renal Cell drug therapy pathology MeSH
- Humans MeSH
- Neoplasm Metastasis MeSH
- Kidney Neoplasms drug therapy pathology MeSH
- Disease-Free Survival MeSH
- Disease Progression MeSH
- Antineoplastic Agents administration & dosage adverse effects therapeutic use MeSH
- Pyrroles administration & dosage adverse effects therapeutic use MeSH
- Registries MeSH
- Retrospective Studies MeSH
- Aged MeSH
- Sunitinib MeSH
- Age Factors MeSH
- Dose-Response Relationship, Drug MeSH
- Check Tag
- Humans MeSH
- Aged MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Czech Republic MeSH
- Names of Substances
- Indoles MeSH
- Antineoplastic Agents MeSH
- Pyrroles MeSH
- Sunitinib MeSH
BACKGROUND: Although a significant proportion of patients with metastatic renal cell carcinoma (mRCC) are elderly, the data on the outcomes of targeted therapies in this population are limited. The aim of the present retrospective registry-based study was to analyse efficacy and toxicity of sunitinib as the first-line targeted therapy of elderly mRCC patients. PATIENTS AND METHODS: The national RENal information system registry of mRCC patients treated with targeted agents in the Czech Republic was used as the data source. Of the 1315 patients treated with sunitinib as first-line targeted therapy, 1016 and 299 patients were aged <70 and ≥70 years, respectively. RESULTS: Elderly patients had a significantly longer interval from diagnosis to the initiation of therapy. Median progression-free survival was 10.8 months (95 % confidence interval 9.8-11.8) and 8.8 months (7.2-10.4) for patients aged <70 and ≥70 years, respectively (p = 0.321). Median overall survival was 31.9 months (27.9-35.9) and 26.3 months (21.3-31.2), respectively (p = 0.044). Significantly more elderly patients started on a reduced dose of sunitinib or discontinued the treatment prior to progression because of adverse events. CONCLUSIONS: The differences in patient profile and dose-reduction rates point to a different approach in the management of older and younger patients in daily clinical practice. The lower dose intensity of sunitinib in the elderly population may have translated into inferior survival.
Biomedical Centre Faculty of Medicine in Pilsen Charles University Prague Czech Republic
Department of Oncology and Radiotherapy University Hospital Pilsen Czech Republic
Institute of Biostatistics and Analyses Faculty of Medicine Masaryk University Brno Czech Republic
See more in PubMed
Crit Rev Oncol Hematol. 2009 Jan;69(1):64-72 PubMed
Expert Rev Anticancer Ther. 2016;16(3):323-34 PubMed
Med Oncol. 2012 Dec;29(5):3314-20 PubMed
Br J Cancer. 2014 Mar 4;110(5):1125-32 PubMed
Ann Oncol. 2013 Feb;24(2):336-42 PubMed
Eur J Cancer. 2009 Jan;45(2):228-47 PubMed
J Clin Oncol. 2002 Jan 1;20(1):289-96 PubMed
Lancet Oncol. 2009 Aug;10 (8):757-63 PubMed
Cancer Treat Rev. 2008 May;34(3):193-205 PubMed
J Clin Oncol. 2009 Aug 1;27(22):3584-90 PubMed
